PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY, CD4+

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。本研究对输注CD4+T细胞的安全性、存活率和抗肿瘤效果进行了评价。CD4+T细胞会产生自己的生长因子，并可能在输注后存活较长时间。这是一项剂量递增研究，其中针对黑色素瘤细胞上发现的一种抗原的递增剂量的CD4T细胞以三种不同的水平给予。这项研究的结果指标包括毒性、输注后T细胞的存活率、肿瘤缩小以及T细胞输注后肿瘤靶向抗原表达的丧失。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The safety, survival and anti-tumor effect of infusions of CD4+ T cells are evaluated in this study. CD4 + T cells produce their own growth factors and may survive for prolonged periods after infusion. This is a dose escalation study in which increasing doses of CD4 T cells targeting an antigen found on melanoma cells are given at three different levels. Outcome measures for this study include toxicity, T cell survival after infusion, tumor shrinkage, and loss of targeted antigen expression by the tumor after T cell infusion.